Elekta, a Swedish medical technology company that offers image guided clinical solutions, has rolled out its advanced radiosurgery system, Elekta Esprit.
The system is said to provide rapid automated treatment planning for clinicians, more personalised treatments for patients, and superior precision while protecting the patient’s functions and spirit.
Elekta said that its new Esprit system will provide a superior visualisation for the clinicians, along with remote accessibility and collaboration tools for the treatment.
Also, the device provides the accuracy to treat even the most challenging targets while delivering a gentler more personalised approach to radiosurgery, said the company.
Esprit leverages Leksell Gamma Knife to provide an accuracy of <0.3mm and offers flexible workflow options based on a single session, fractionated, adaptive protocols.
Elekta president and CEO Gustaf Salford said: “Esprit will allow clinicians to take radiosurgery to the next level and treat patients with the highest accuracy, protecting their mind and memories and enabling a higher quality of life.
“Continuing the Leksell Gamma Knife tradition, Elekta yet again redefines what was thought possible in stereotactic radiosurgery.”
In a separate development, Elekta has entered a 10-year strategic partnership and R&D alliance with the Netherlands Cancer Institute to develop a new generation of radiation therapy solutions for cancer patients.
The agreement builds on Elekta’s existing collaboration with the institute for more than two decades, which started with the development of Image Guided Radiation Therapy (IGRT).
Under the collaboration, Elekta and the Netherlands Cancer Institute will combine their resources, knowledge, and expertise to improve Elekta’s Unity and linac solutions.
The solutions will enhance imaging, personalised and adaptive radiotherapy, novel treatment delivery approaches, artificial intelligence and software solutions.
In addition, the Netherlands Cancer Institute will switch to Elekta’s new treatment management solution, developed in partnership with Philips.
Elekta chief product officer Maurits Wolleswinkel said: “With this agreement, we will jointly further shape the future of radiation therapy through our research and product development relations.”
Netherlands Cancer Institute medical physics radiotherapy head Anke van Mourik said: “The strength of this collaboration is the synergy in visions, the mutual innovative force and the close collaboration between research and the clinic.”
